INFECTION RESISTANT POLYURETHANE MATERIALS

Information

  • Research Project
  • 2867221
  • ApplicationId
    2867221
  • Core Project Number
    R41HL062764
  • Full Project Number
    1R41HL062764-01
  • Serial Number
    62764
  • FOA Number
  • Sub Project Id
  • Project Start Date
    5/1/1999 - 25 years ago
  • Project End Date
    4/30/2000 - 24 years ago
  • Program Officer Name
  • Budget Start Date
    5/1/1999 - 25 years ago
  • Budget End Date
    4/30/2000 - 24 years ago
  • Fiscal Year
    1999
  • Support Year
    1
  • Suffix
  • Award Notice Date
    4/26/1999 - 25 years ago

INFECTION RESISTANT POLYURETHANE MATERIALS

DESCRIPTION: (adapted from the applicant's abstract). Biomaterial infection is a topic of concern with considerable human and economic costs. The investigators seek to develop infection -- resistant polyurethanes using techniques from polymer chemistry, textile science and biomedical research. Their university collaborators' have generated infection-resistant polyester materials that do not require modification of polymer or the need for binder materials. They have hypothesized that quinoline antibiotics can "dye" biomedically-useful polyurethanes using standard textile dyeing techniques to produce clinically useful materials with long-term infection resistance. The proposal is to optimize and characterize the uptake of Ciprofloxacin by polycarbonate-based polyurethanes. The release of the antibiotic will be examined spectrophotometrically and using standard microbiological techniques. PROPOSED COMMERCIAL APPLICATION: Development of a polyurethane biomaterial with long-term infection resistance has applications in wa wide range of implantable devices, such as indwelling catheters, vascular grafts, stents, and as coatings on existing catheters. Infections of these products is a topic of current and growing concern with considerable economic cost. For example, around 50- 100,000 indwelling catheters become infected every year in the U.S. with concomitant human suffering and cost implications. Conservative estimates indicate that the U.S. market for such infection-resistant products in greater than $300 million annually.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R41
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
  • Organization Name
    CARDIOTECH INTERNATIONAL, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    WOBURN
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    01801
  • Organization District
    UNITED STATES